Royalty Pharma EBITDA 2019-2024 | RPRX

Royalty Pharma EBITDA for the quarter ending September 30, 2024 was $0.740B, a 373.26% increase year-over-year.

  • Royalty Pharma 2023 EBITDA was 1.513B, a 352.77% increase from 2022.
  • Royalty Pharma 2022 EBITDA was 0.334B, a 77.33% decline from 2021.
  • Royalty Pharma 2021 EBITDA was 1.474B, a 9.59% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Royalty Pharma EBITDA 2019-2024 | RPRX

  • Royalty Pharma 2023 EBITDA was 1.513B, a 352.77% increase from 2022.
  • Royalty Pharma 2022 EBITDA was 0.334B, a 77.33% decline from 2021.
  • Royalty Pharma 2021 EBITDA was 1.474B, a 9.59% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
American Express (AXP)$202B
Blackstone (BX)$127.3B
Moody's (MCO)$84.4B
Orix Corp Ads (IX)$25.9B
Synchrony Financial (SYF)$25.2B
Brookfield Asset Management (BAM)$24.8B
Grupo Financiero Banorte SAB De CV (GBOOY)$21.2B
Equitable Holdings (EQH)$15.1B
Jefferies Financial Group (JEF)$14.5B
Houlihan Lokey (HLI)$12.8B
SoFi Technologies (SOFI)$12.7B
Daiwa Securities Group (DSEEY)$10.1B
XP (XP)$9.7B
Globe Life (GL)$9.1B
Brookfield Wealth Solutions (BNT)$8.4B
Jackson Financial (JXN)$8.4B
SouthState (SSB)$8.2B
StepStone Group (STEP)$7.2B
Lazard (LAZ)$6.6B
Freedom Holding (FRHC)$6.5B
Blue Owl Capital (OBDC)$5.8B
Rithm Capital (RITM)$5.5B
Virtu Financial (VIRT)$5.2B
Upstart Holdings (UPST)$5B
Core Scientific (CORZ)$4.6B
Euronet Worldwide (EEFT)$4.5B
AXOS FINANCIAL, INC (AX)$4.5B
PJT Partners (PJT)$3.8B
HA Sustainable Infrastructure Capital (HASI)$3.7B
Community Financial System (CBU)$3.6B